 <h1>Tekturna HCT Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>aliskiren / hydrochlorothiazide</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about aliskiren / hydrochlorothiazide. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Tekturna HCT.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to aliskiren/hydrochlorothiazide: oral tablet</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet)</p><p>When pregnancy is detected, discontinue aliskiren / hydrochlorothiazide as soon as possible, since drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, aliskiren / hydrochlorothiazide may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking aliskiren / hydrochlorothiazide:</p><p>
<i>Less common</i>
</p><ul>
<li>Chills</li>
<li>cough</li>
<li>diarrhea</li>
<li>fever</li>
<li>general feeling of discomfort or illness</li>
<li>headache</li>
<li>joint pain</li>
<li>loss of appetite</li>
<li>muscle aches and pains</li>
<li>nausea</li>
<li>runny nose</li>
<li>shivering</li>
<li>sore throat</li>
<li>sweating</li>
<li>trouble sleeping</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Agitation</li>
<li>blistering, peeling, loosening of skin</li>
<li>blurred vision</li>
<li>coma</li>
<li>confusion</li>
<li>decreased interest in sexual intercourse</li>
<li>decreased urine output</li>
<li>depression</li>
<li>difficulty with swallowing</li>
<li>dizziness</li>
<li>drowsiness</li>
<li>eye pain</li>
<li>fast heartbeat</li>
<li>hives, itching, skin rash</li>
<li>hostility</li>
<li>inability to have or keep an erection</li>
<li>incoherent speech</li>
<li>increased thirst</li>
<li>irregular heartbeat</li>
<li>irritability</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>loss in sexual ability, desire, drive, or performance</li>
<li>loss of appetite</li>
<li>lethargy</li>
<li>metallic taste</li>
<li>muscle twitching or weakness</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>rapid weight gain</li>
<li>red, irritated eyes</li>
<li>seizures</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>trouble breathing</li>
<li>tightness in the chest</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking aliskiren / hydrochlorothiazide:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Coma</li>
<li>confusion</li>
<li>decreased urine output</li>
<li>drowsiness</li>
<li>dry mouth</li>
<li>fainting</li>
<li>increase in heart rate</li>
<li>increased thirst</li>
<li>irregular heartbeat</li>
<li>irritability</li>
<li>lightheadedness</li>
<li>muscle cramps</li>
<li>numbness, tingling, pain, or weakness in the hands or feet</li>
<li>rapid breathing</li>
<li>seizures</li>
<li>sunken eyes</li>
<li>swelling of the face, ankles, or hands</li>
<li>trembling</li>
<li>weak pulse</li>
<li>weakness and heaviness of the legs</li>
<li>wrinkled skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of aliskiren / hydrochlorothiazide may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Difficulty with moving</li>
<li>feeling of constant movement of self or surroundings</li>
<li>lack or loss of strength</li>
<li>muscle stiffness</li>
<li>sensation of spinning</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to aliskiren / hydrochlorothiazide: oral tablet</i></p><h3>Hypersensitivity</h3><p>Aliskiren:</p>
<p><b>Frequency not reported</b>: Angioedema (face, hands, and body) with or without respiratory symptoms</p>
<p><b>Postmarketing reports</b>: Angioedema</p>
<p></p>
<p>Hydrochlorothiazide:</p>
<p><b>Uncommon</b> (0.1% to 1%): Rash </p>
<p><b>Rare</b> (less than 0.1%): Anaphylaxis<sup>[Ref]</sup></p><p>Two cases of angioedema with respiratory symptoms were reported with aliskiren use in clinical studies, and two other cases of periorbital edema without respiratory symptoms were reported as possible angioedema and resulted in discontinuation.  The rate of angioedema cases in completed studies was 0.06%.  Twenty-six other cases of edema involving the face, hands, or whole body were reported with aliskiren use, including four which led to discontinuation.  In the placebo controlled studies, the incidence of edema involving the face, hands or whole body was 0.4% with aliskiren compared with 0.5% with placebo.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Edema, peripheral edema</p>
<p></p>
<p>Aliskiren:</p>
<p><b>Uncommon</b> (0.1% to 1%): Elevated uric acid, gout, renal stones</p>
<p><b>Postmarketing reports</b>: Peripheral edema, hyponatremia</p>
<p></p>
<p>Hydrochlorothiazide:</p>
<p><b>Very common</b> (10% or more): Mild hypokalemia (decrease of 0.5 mEq/L) occurs in up to 50% of patients, and may predispose patients to cardiac arrhythmias</p>
<p><b>Common</b> (1% to 10%): Metabolic alkalosis, hyponatremia, hypomagnesemia, hypercalcemia, hyperglycemia, elevated serum uric acid levels</p>
<p><b>Very rare</b> (less than 0.01%): Hot flushes</p>
<p><b>Frequency not reported</b>: Edema, peripheral edema, glucose intolerance, a potentially deleterious effect on the lipid profile (i.e., increased serum cholesterol)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>In women and the elderly (65 years of age or older) receiving aliskiren therapy, increases in diarrhea rates were evident starting at a dose of 150 mg daily.  Diarrhea and other GI symptoms were typically mild and rarely led to discontinuation.<sup>[Ref]</sup></p><p>Aliskiren:</p>
<p><b>Common</b> (1% to 10%): Diarrhea, abdominal pain, dyspepsia, gastroesophageal reflux (these side effects appear to be dose related)</p>
<p><b>Postmarketing reports</b>: Nausea, vomiting</p>
<p></p>
<p>Hydrochlorothiazide:</p>
<p><b>Uncommon</b> (0.1% to 1%): Nausea, vomiting, diarrhea<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Aliskiren:</p>
<p><b>Common</b> (1% to 10%): Rash</p>
<p><b>Rare</b> (less than 0.1%): Angioedema (involving the face, hands, or whole body)</p>
<p><b>Postmarketing reports</b>: Severe cutaneous adverse reactions (including Stevens Johnson syndrome and toxic epidermal necrolysis)</p>
<p></p>
<p>Hydrochlorothiazide:</p>
<p><b>Rare</b> (less than 0.1%): Erythema annular centrifugum, acute eczematous dermatitis, morbilliform and leukocytoclastic vasculitis, phototoxic dermatitis</p>
<p><b>Frequency not reported</b>: Subacute cutaneous lupus erythematosus like reaction<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Uncommon</b> (0.1% to 1%): Malaise, pain</p>
<p><b>Frequency not reported</b>: Fatigue</p>
<p></p>
<p>Aliskiren:</p>
<p><b>Frequency not reported</b>: Headache, dizziness, fatigue, episodes of tonic-clonic seizures with loss of consciousness</p>
<p></p>
<p>Hydrochlorothiazide:</p>
<p><b>Frequency not reported</b>: Cerebrovascular insufficiency associated with hydrochlorothiazide-induced plasma volume contraction, cognitive and neurologic impairment (i.e., confusion, somnolence, feeling dazed)- Symptoms resolved following discontinuation of hydrochlorothiazide.<sup>[Ref]</sup></p><p>Episodes of tonic-clonic seizures were reported in two patients treated with aliskiren in the clinical trials.  One patient had predisposing causes for seizures and a negative electroencephalogram (EEG) and cerebral imaging following the seizures (the other patient's EEG and imaging results were not reported).  Aliskiren was discontinued and there was no rechallenge.<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Occasional elevations (greater than 150% from baseline) in ALT (SGPT)</p>
<p></p>
<p>Hydrochlorothiazide:</p>
<p><b>Rare</b> (less than 0.1%): Interstitial nephritis<sup>[Ref]</sup></p><h3>Renal</h3><p>Hydrochlorothiazide:</p>
<p><b>Rare</b> (less than 0.1%): Renal insufficiency, renal failure, renal dysfunction, interstitial nephritis<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Hydrochlorothiazide:</p>
<p><b>Rare</b> (less than 0.1%): Immune-complex hemolytic anemia, aplastic anemia, thrombocytopenia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Asthenia, rigors</p>
<p></p>
<p>Hydrochlorothiazide:</p>
<p><b>Uncommon</b> (0.1% to 1%): Myalgias, chills, muscle spasms, preservation of mineral bone density in older patients<sup>[Ref]</sup></p><h3>Ocular</h3><p>Hydrochlorothiazide:</p>
<p><b>Frequency not reported</b>: Transient blurred vision, acute transient myopia, acute angle-closure glaucoma, xanthopsia<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Aliskiren:</p>
<p><b>Frequency not reported</b>: Nasopharyngitis, upper respiratory tract infection, cough</p>
<p></p>
<p>Hydrochlorothiazide:</p>
<p><b>Frequency not reported</b>: Acute noncardiogenic pulmonary edema (these cases are thought to be due to idiosyncrasy or a hypersensitivity mechanism)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Rare</b> (less than 0.1%): Parosmia</p>
<p><b>Frequency not reported</b>: Tinnitus<sup>[Ref]</sup></p><h3>Immunologic</h3><p>Hydrochlorothiazide:</p>
<p><b>Common</b> (1% to 10%): Rash that is histologically identical to subacute cutaneous lupus</p>
<p><b>Frequency not reported</b>: Allergic vasculitis, hemolytic anemia</p><h3>Cardiovascular</h3><p>Aliskiren:</p>
<p><b>Rare</b> (less than 0.1%): Hypotension</p>
<p></p>
<p>Hydrochlorothiazide:</p>
<p><b>Frequency not reported</b>: Cardiac arrhythmias (including ventricular ectopy and complete AV heart block), hypotension, orthostatic hypotension (more common in the elderly)<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Tekturna HCT (aliskiren-hydrochlorothiazide)." Novartis Pharmaceuticals, East Hanover, NJ. </p><p id="ref_2">2. "Product Information. Tekturna (aliskiren)." Novartis Pharmaceuticals, East Hanover, NJ. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Tekturna HCT (aliskiren / hydrochlorothiazide)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>4 Reviews</li>
<li>Drug class: miscellaneous antihypertensive combinations</li>
<li>FDA Alerts (1)</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Tekturna HCT &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
<h3>Other Formulations</h3>
<ul class="more-resources-list more-resources-list-formulations">
<li>Tekturna</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>High Blood Pressure</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to aliskiren / hydrochlorothiazide: oral tablet</i></p><h3>Hypersensitivity</h3><p>Aliskiren:</p><p><b>Frequency not reported</b>: Angioedema (face, hands, and body) with or without respiratory symptoms</p><p><b>Postmarketing reports</b>: Angioedema</p><p></p><p>Hydrochlorothiazide:</p><p><b>Uncommon</b> (0.1% to 1%): Rash </p><p><b>Rare</b> (less than 0.1%): Anaphylaxis<sup>[Ref]</sup></p><p>Two cases of angioedema with respiratory symptoms were reported with aliskiren use in clinical studies, and two other cases of periorbital edema without respiratory symptoms were reported as possible angioedema and resulted in discontinuation.  The rate of angioedema cases in completed studies was 0.06%.  Twenty-six other cases of edema involving the face, hands, or whole body were reported with aliskiren use, including four which led to discontinuation.  In the placebo controlled studies, the incidence of edema involving the face, hands or whole body was 0.4% with aliskiren compared with 0.5% with placebo.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Edema, peripheral edema</p><p></p><p>Aliskiren:</p><p><b>Uncommon</b> (0.1% to 1%): Elevated uric acid, gout, renal stones</p><p><b>Postmarketing reports</b>: Peripheral edema, hyponatremia</p><p></p><p>Hydrochlorothiazide:</p><p><b>Very common</b> (10% or more): Mild hypokalemia (decrease of 0.5 mEq/L) occurs in up to 50% of patients, and may predispose patients to cardiac arrhythmias</p><p><b>Common</b> (1% to 10%): Metabolic alkalosis, hyponatremia, hypomagnesemia, hypercalcemia, hyperglycemia, elevated serum uric acid levels</p><p><b>Very rare</b> (less than 0.01%): Hot flushes</p><p><b>Frequency not reported</b>: Edema, peripheral edema, glucose intolerance, a potentially deleterious effect on the lipid profile (i.e., increased serum cholesterol)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>In women and the elderly (65 years of age or older) receiving aliskiren therapy, increases in diarrhea rates were evident starting at a dose of 150 mg daily.  Diarrhea and other GI symptoms were typically mild and rarely led to discontinuation.<sup>[Ref]</sup></p><p>Aliskiren:</p><p><b>Common</b> (1% to 10%): Diarrhea, abdominal pain, dyspepsia, gastroesophageal reflux (these side effects appear to be dose related)</p><p><b>Postmarketing reports</b>: Nausea, vomiting</p><p></p><p>Hydrochlorothiazide:</p><p><b>Uncommon</b> (0.1% to 1%): Nausea, vomiting, diarrhea<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Aliskiren:</p><p><b>Common</b> (1% to 10%): Rash</p><p><b>Rare</b> (less than 0.1%): Angioedema (involving the face, hands, or whole body)</p><p><b>Postmarketing reports</b>: Severe cutaneous adverse reactions (including Stevens Johnson syndrome and toxic epidermal necrolysis)</p><p></p><p>Hydrochlorothiazide:</p><p><b>Rare</b> (less than 0.1%): Erythema annular centrifugum, acute eczematous dermatitis, morbilliform and leukocytoclastic vasculitis, phototoxic dermatitis</p><p><b>Frequency not reported</b>: Subacute cutaneous lupus erythematosus like reaction<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Uncommon</b> (0.1% to 1%): Malaise, pain</p><p><b>Frequency not reported</b>: Fatigue</p><p></p><p>Aliskiren:</p><p><b>Frequency not reported</b>: Headache, dizziness, fatigue, episodes of tonic-clonic seizures with loss of consciousness</p><p></p><p>Hydrochlorothiazide:</p><p><b>Frequency not reported</b>: Cerebrovascular insufficiency associated with hydrochlorothiazide-induced plasma volume contraction, cognitive and neurologic impairment (i.e., confusion, somnolence, feeling dazed)- Symptoms resolved following discontinuation of hydrochlorothiazide.<sup>[Ref]</sup></p><p>Episodes of tonic-clonic seizures were reported in two patients treated with aliskiren in the clinical trials.  One patient had predisposing causes for seizures and a negative electroencephalogram (EEG) and cerebral imaging following the seizures (the other patient's EEG and imaging results were not reported).  Aliskiren was discontinued and there was no rechallenge.<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Occasional elevations (greater than 150% from baseline) in ALT (SGPT)</p><p></p><p>Hydrochlorothiazide:</p><p><b>Rare</b> (less than 0.1%): Interstitial nephritis<sup>[Ref]</sup></p><h3>Renal</h3><p>Hydrochlorothiazide:</p><p><b>Rare</b> (less than 0.1%): Renal insufficiency, renal failure, renal dysfunction, interstitial nephritis<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Hydrochlorothiazide:</p><p><b>Rare</b> (less than 0.1%): Immune-complex hemolytic anemia, aplastic anemia, thrombocytopenia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Asthenia, rigors</p><p></p><p>Hydrochlorothiazide:</p><p><b>Uncommon</b> (0.1% to 1%): Myalgias, chills, muscle spasms, preservation of mineral bone density in older patients<sup>[Ref]</sup></p><h3>Ocular</h3><p>Hydrochlorothiazide:</p><p><b>Frequency not reported</b>: Transient blurred vision, acute transient myopia, acute angle-closure glaucoma, xanthopsia<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Aliskiren:</p><p><b>Frequency not reported</b>: Nasopharyngitis, upper respiratory tract infection, cough</p><p></p><p>Hydrochlorothiazide:</p><p><b>Frequency not reported</b>: Acute noncardiogenic pulmonary edema (these cases are thought to be due to idiosyncrasy or a hypersensitivity mechanism)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Rare</b> (less than 0.1%): Parosmia</p><p><b>Frequency not reported</b>: Tinnitus<sup>[Ref]</sup></p><h3>Immunologic</h3><p>Hydrochlorothiazide:</p><p><b>Common</b> (1% to 10%): Rash that is histologically identical to subacute cutaneous lupus</p><p><b>Frequency not reported</b>: Allergic vasculitis, hemolytic anemia</p><h3>Cardiovascular</h3><p>Aliskiren:</p><p><b>Rare</b> (less than 0.1%): Hypotension</p><p></p><p>Hydrochlorothiazide:</p><p><b>Frequency not reported</b>: Cardiac arrhythmias (including ventricular ectopy and complete AV heart block), hypotension, orthostatic hypotension (more common in the elderly)<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Tekturna HCT (aliskiren-hydrochlorothiazide)." Novartis Pharmaceuticals, East Hanover, NJ. </p><p id="ref_2">2. "Product Information. Tekturna (aliskiren)." Novartis Pharmaceuticals, East Hanover, NJ. </p><h2>More about Tekturna HCT (aliskiren / hydrochlorothiazide)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>4 Reviews</li>
<li>Drug class: miscellaneous antihypertensive combinations</li>
<li>FDA Alerts (1)</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Tekturna HCT &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Other Formulations</h3><ul class="more-resources-list more-resources-list-formulations">
<li>Tekturna</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>High Blood Pressure</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>